Exclusive Summary

• Proven Equivalence: UB493 is a Bevacizumab biosimilar with Phase III clinical trials completed, featuring a head-to-head study against Roche's Avastin®.
• High-Demand Indications: Targets Non-Small Cell Lung Cancer (nsNSCLC) and Metastatic Colorectal Cancer, addressing substantial global oncology needs.
• Commercial Readiness: With clinical risks mitigated, the product is positioned for rapid registration and market entry (NDA-ready stage).
• Strategic Value: Offers a cost-effective biologic solution, ideal for partners seeking to capture market share in price-sensitive regions or expand oncology portfolios.

Asset Materials

Contact Us for Full Materials